INTRODUCTION: Brain metastases (BM) from breast cancer are associated with poor prognosis. This study was made to determine the prognostic influence of breast cancer biological subtypes, and to define the best therapeutic options in this setting, with a special focus on the HER2-positive population. PATIENTS AND METHODS: Breast cancer patients with known hormone receptors (HR) and HER2 status presenting with BM treated between 1995 and 2010 in our two institutions were considered for this retrospective study. RESULTS: 250 patients were included. The study population consisted of 25.6% patients categorized as triple-negative (HR-/HER2-), 30.8% as HR+/HER2- and 43.6% as HER2+ breast cancer. Median overall survival (OS) was 8.9 months (95% CI, 6.9-10.3 months). Cerebral progression remained the most frequent cause of death (57.1%). On multivariate analysis, HER2 positivity and the RPA score were the two most important prognostic factors. Local treatment (surgery or stereotactic radiotherapy) and chemotherapy were significantly associated with an increased survival. On multivariate analysis of the RPA1-2 population, local treatment and chemotherapy were independent prognostic factors in addition to biological subtypes, RPA class, liver metastases and clinical signs of intra-cranial hypertension. Anti-HER2 therapies administered after BM diagnosis significantly and independently increased OS. Median OS in patients receiving both trastuzumab and lapatinib after BM diagnosis was significantly better than that the one of patients receiving only one of the 2 targeted therapies (25.7 vs. 9.6 months, p < 0.001). CONCLUSIONS: Biological subtypes are independent prognostic determinants. Chemotherapy and targeted therapies positively affect the prognosis after first BM.
INTRODUCTION: Brain metastases (BM) from breast cancer are associated with poor prognosis. This study was made to determine the prognostic influence of breast cancer biological subtypes, and to define the best therapeutic options in this setting, with a special focus on the HER2-positive population. PATIENTS AND METHODS: Breast cancerpatients with known hormone receptors (HR) and HER2 status presenting with BM treated between 1995 and 2010 in our two institutions were considered for this retrospective study. RESULTS: 250 patients were included. The study population consisted of 25.6% patients categorized as triple-negative (HR-/HER2-), 30.8% as HR+/HER2- and 43.6% as HER2+ breast cancer. Median overall survival (OS) was 8.9 months (95% CI, 6.9-10.3 months). Cerebral progression remained the most frequent cause of death (57.1%). On multivariate analysis, HER2 positivity and the RPA score were the two most important prognostic factors. Local treatment (surgery or stereotactic radiotherapy) and chemotherapy were significantly associated with an increased survival. On multivariate analysis of the RPA1-2 population, local treatment and chemotherapy were independent prognostic factors in addition to biological subtypes, RPA class, liver metastases and clinical signs of intra-cranial hypertension. Anti-HER2 therapies administered after BM diagnosis significantly and independently increased OS. Median OS in patients receiving both trastuzumab and lapatinib after BM diagnosis was significantly better than that the one of patients receiving only one of the 2 targeted therapies (25.7 vs. 9.6 months, p < 0.001). CONCLUSIONS: Biological subtypes are independent prognostic determinants. Chemotherapy and targeted therapies positively affect the prognosis after first BM.
Authors: Agnieszka Szadurska; Elżbieta Pluta; Tomasz Walasek; Paweł Blecharz; Jerzy Jakubowicz; Jerzy W Mituś Journal: Contemp Oncol (Pozn) Date: 2017-01-12
Authors: Khawaja F Zahid; Shiyam Kumar; Khalid Al-Bimani; Tanweer Ahmed; Adil Al-Ajmi; Ikram A Burney; Mansour Al-Moundhri Journal: Oman Med J Date: 2019-09
Authors: C A Sartorius; C T Hanna; B Gril; H Cruz; N J Serkova; K M Huber; P Kabos; T B Schedin; V F Borges; P S Steeg; D M Cittelly Journal: Oncogene Date: 2015-09-28 Impact factor: 9.867
Authors: María J Contreras-Zárate; D Ryan Ormond; Austin E Gillen; Colton Hanna; Nicole L Day; Natalie J Serkova; Britta M Jacobsen; Susan M Edgerton; Ann D Thor; Virginia F Borges; Kevin O Lillehei; Michael W Graner; Peter Kabos; Diana M Cittelly Journal: Front Oncol Date: 2017-11-02 Impact factor: 6.244